Skip to main content

Table 3 Percentages of resistant phenotypes among Gram-positive and Gram—negative isolates by year, 2004–2012

From: A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in France between 2004 and 2012

Pathogen

 

2004

2005

2006

2007

2008

2009

2010

2011

2012

2004-12

 

N

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Gram-positive

           

E. faecalis, VRE

969

0 (0.0)

0 (0.0)

1 (1.5)

0 (0.0)

0 (0.0)

2 (1.1)

1 (0.7)

1 (3.8)

2 (1.3)

7 (0.7)

E. faecium, VRE

332

0 (0.0)

0 (0.0)

0 (0.0)

2 (4.9)

8 (10.8)

2 (3.3)

3 (5.5)

1 (6.7)

2 (4.3)

18 (5.4)

S. aureus, MRSA

2229

34 (34.3)

20 (31.7)

40 (30.5)

88 (29.6)

135 (28.2)

77 (20.0)

75 (26.1)

15 (23.4)

147 (34.7)

631 (28.3)

S. pneumoniae, PRSP

990

0 (0.0)

1 (3.4)

3 (4.6)

3 (2.0)

9 (4.5)

7 (4.0)

6 (4.1)

0 (0.0)

3 (2.0)

32 (3.2)

Gram-negative

           

A. baumannii, MDR

1161

0 (0.0)

0 (0.0)

2 (2.0)

7 (4.9)

12 (5.2)

12 (5.2)

13 (6.7)

1 (3.0)

7 (4.7)

54 (4.7)

E. coli, ESBL

2284

3 (3.0)

2 (3.7)

8 (4.6)

18 (6.5)

58 (11.8)

75 (17.5)

46 (13.9)

13 (16.9)

52 (14.9)

275 (12.0)

H. influenzae, BL-Pos

1191

13 (23.2)

6 (23.1)

17 (27.4)

30 (18.1)

53 (21.1)

56 (25.0)

36 (23.7)

13 (27.7)

45 (21.7)

269 (22.6)

K. pneumoniae, ESBL

1524

5 (7.6)

5 (9.3)

9 (10.3)

20 (12.3)

64 (18.6)

47 (16.4)

58 (24.9)

11 (22.0)

55 (23.0)

274 (18.0)

P. aeruginosa, MDR

1780

2 (2.5)

0 (0.0)

17 (11.2)

23 (10.7)

39 (10.2)

37 (11.0)

33 (12.5)

9 (14.8)

21 (8.1)

181 (10.2)

  1. ESBL, extended-spectrum β-lactamase; BL-Pos, β-lactamase-positive; MDR, multidrug-resistant; MRSA, methicillin-resistant S. aureus; PRSP, penicillin-resistant S. pneumoniae; VRE, vancomycin-resistant Enterococcus.
  2. Results do not exactly match those presented by Nørskov-Lauritsen et al. [7] due to subsequent addition and deletion of isolates from the T.E.S.T. database.